Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release methylphenidate for theory of mind in children with ADHD
IRCT20190827044633N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Theory of mind ability and ADHD severity. Started Sep 2019; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20190827044633N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190827044633N1.